Brokers Set Expectations for Pyxis Oncology FY2024 Earnings

Pyxis Oncology, Inc. (NASDAQ:PYXS) – Equities research analysts at William Blair dropped their FY2024 EPS estimates for Pyxis Oncology in a research report issued on Tuesday, November 12th. William Blair analyst A. Hsieh now expects that the company will post earnings per share of ($1.02) for the year, down from their previous forecast of ($1.00). The consensus estimate for Pyxis Oncology’s current full-year earnings is ($1.04) per share. William Blair also issued estimates for Pyxis Oncology’s Q4 2024 earnings at ($0.30) EPS, Q3 2025 earnings at ($0.31) EPS, Q4 2025 earnings at ($0.31) EPS, FY2025 earnings at ($1.26) EPS and FY2026 earnings at ($1.32) EPS.

Pyxis Oncology (NASDAQ:PYXS) last announced its earnings results on Wednesday, August 14th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.04.

Other equities analysts also recently issued research reports about the stock. Stifel Nicolaus assumed coverage on shares of Pyxis Oncology in a research note on Thursday, August 8th. They set a “buy” rating and a $10.00 price objective on the stock. HC Wainwright reiterated a “buy” rating and set a $7.00 target price on shares of Pyxis Oncology in a research report on Friday, August 16th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $7.00 price objective on shares of Pyxis Oncology in a research note on Thursday, September 19th. Finally, Stephens initiated coverage on shares of Pyxis Oncology in a research report on Friday, November 8th. They issued an “overweight” rating and a $13.00 target price on the stock. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Pyxis Oncology presently has a consensus rating of “Buy” and an average price target of $9.57.

Pyxis Oncology Stock Performance

Pyxis Oncology stock opened at $4.19 on Friday. Pyxis Oncology has a fifty-two week low of $1.35 and a fifty-two week high of $6.85. The stock has a fifty day moving average of $3.69 and a two-hundred day moving average of $3.65. The company has a market capitalization of $249.16 million, a price-to-earnings ratio of -4.07 and a beta of 1.27.

Institutional Investors Weigh In On Pyxis Oncology

Several hedge funds have recently modified their holdings of the stock. Bank of New York Mellon Corp boosted its position in shares of Pyxis Oncology by 92.2% in the second quarter. Bank of New York Mellon Corp now owns 311,630 shares of the company’s stock worth $1,031,000 after buying an additional 149,522 shares during the period. abrdn plc boosted its holdings in shares of Pyxis Oncology by 28.9% during the third quarter. abrdn plc now owns 913,045 shares of the company’s stock worth $3,351,000 after purchasing an additional 204,742 shares during the period. Millennium Management LLC grew its position in Pyxis Oncology by 125.3% during the second quarter. Millennium Management LLC now owns 1,336,908 shares of the company’s stock valued at $4,425,000 after purchasing an additional 743,499 shares in the last quarter. Blue Owl Capital Holdings LP purchased a new stake in Pyxis Oncology in the 2nd quarter worth approximately $3,462,000. Finally, SG Americas Securities LLC acquired a new stake in shares of Pyxis Oncology during the 1st quarter valued at $59,000. 39.09% of the stock is owned by hedge funds and other institutional investors.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.